CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE

505(b)(2) Clinical Trials for Fluoxetine Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03228732 ↗	The Effects of Fluoxetine and/or DHEA	Recruiting	University of Maryland	Early Phase 1	2017-12-19	(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
OTC	NCT03228732 ↗	The Effects of Fluoxetine and/or DHEA	Recruiting	University of Maryland, Baltimore	Early Phase 1	2017-12-19	(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	National Department of Health, Papua New Guinea	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	Oriol Mitja	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.

All Clinical Trials for Fluoxetine Hydrochloride

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	Columbia University	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	New York State Psychiatric Institute	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000373 ↗	Treatment of Obsessive-Compulsive Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	1992-09-01	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗	Treatment of Obsessive-Compulsive Disorder	Completed	University of Florida	Phase 4	1992-09-01	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.

Clinical Trial Conditions for Fluoxetine Hydrochloride

Condition Name

Condition Name for Fluoxetine Hydrochloride
Intervention	Trials
Depression	62
Major Depressive Disorder	48
Bipolar Disorder	10
Obsessive-Compulsive Disorder	9

Condition MeSH

Condition MeSH for Fluoxetine Hydrochloride
Intervention	Trials
Depression	148
Depressive Disorder	125
Depressive Disorder, Major	77
Disease	63

Clinical Trial Locations for Fluoxetine Hydrochloride

Trials by Country

Trials by Country for Fluoxetine Hydrochloride
Location	Trials
United States	586
Canada	37
China	24
France	19
Mexico	17

Trials by US State

Trials by US State for Fluoxetine Hydrochloride
Location	Trials
New York	48
California	38
Texas	30
Ohio	28
Massachusetts	25

Clinical Trial Progress for Fluoxetine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Fluoxetine Hydrochloride
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for Fluoxetine Hydrochloride
Clinical Trial Phase	Trials
Completed	190
Recruiting	37
Unknown status	28

Clinical Trial Sponsors for Fluoxetine Hydrochloride

Sponsor Name

Sponsor Name for Fluoxetine Hydrochloride
Sponsor	Trials
National Institute of Mental Health (NIMH)	48
Eli Lilly and Company	17
New York State Psychiatric Institute	14

Sponsor Type

Sponsor Type for Fluoxetine Hydrochloride
Sponsor	Trials
Other	446
Industry	90
NIH	73

Clinical Trials Update, Market Analysis, and Projection for Fluoxetine Hydrochloride

Last updated: October 28, 2025

Introduction

Fluoxetine Hydrochloride, a selective serotonin reuptake inhibitor (SSRI), remains a cornerstone in treating major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. Initially approved by the FDA in 1987 under the brand name Prozac, its extensive clinical use has spurred ongoing research, market dynamics, and future growth trajectories. This comprehensive analysis offers an in-depth update on recent clinical trials, evaluates current market conditions, and projects future trends for Fluoxetine Hydrochloride.

Clinical Trials Update

Recent Clinical Research and Development Activity

Over the past two years, the landscape of clinical trials for Fluoxetine Hydrochloride has shifted from landmark efficacy studies to exploratory investigations targeting novel indications, formulations, and combination therapies.

• New Indication Trials:
  Recent phase II and III trials have explored fluoxetine’s potential in neurodevelopmental disorders, such as autism spectrum disorder (ASD) and post-traumatic stress disorder (PTSD). Notably, a 2022 study published in Neuropsychopharmacology evaluated fluoxetine’s efficacy in reducing repetitive behaviors in ASD, indicating promising symptomatic benefits with an acceptable safety profile (approvals pending regulatory review).

• Formulation Innovations:
  There is increasing interest in controlled-release formulations to enhance patient adherence and minimize side effects. A 2021 trial assessed a once-weekly oral controlled-release fluoxetine, showing comparable efficacy to daily dosing with improved compliance.

• Combination and Augmentation Strategies:
  Emerging research investigates fluoxetine as part of combination regimens, especially with atypical antipsychotics and novel agents targeting neuroinflammation pathways. Such trials aim to address treatment-resistant depression and comorbid conditions.

Regulatory and Trial Trends

The clinical trial landscape reflects a cautious yet innovative progression. While large phase III trials continue for established indications, new exploratory trials dominate the pipeline, primarily driven by academic institutions and biotech collaborations.

The Food and Drug Administration (FDA) recently granted Fast Track status to fluoxetine-based therapies for neurodevelopmental disorders, signaling a prioritized regulatory review process and potential expedited approval pathways.

Safety and Efficacy Considerations

Long-term safety data consolidates fluoxetine's profile, with adverse events primarily limited to gastrointestinal disturbances, sexual dysfunction, and rare cases of QT prolongation. However, new trials focusing on pediatric populations and long-term use continue to verify safety, with emerging data supporting its extended use under medical supervision.

Market Analysis

Current Market Landscape

The global antidepressant market, valued at approximately $15 billion in 2022, is characterized by mature competition, with fluoxetine as a leading product impacting approximately 20% of diagnosed patients, particularly in North America and Europe.

• Market Share and Revenue Contributions:
  Fluoxetine, primarily through generic availability post-patent expirations (around 2001), sustains significant sales volume despite declining brand-name sales. In 2022, generic fluoxetine contributed to an estimated $4 billion globally, with North America accounting for over 60%, reflecting high prescription rates and entrenched clinical use.

• Emerging Markets:
  Asia-Pacific nations, especially China and India, exhibit increasing uptake driven by growing mental health awareness and expanding healthcare infrastructure. The rising prevalence of depression and anxiety disorders supports ongoing demand.

Competitive Dynamics

The antidepressant market faces intense competition from newer pharmacological classes such as serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and novel agents like ketamine. Nevertheless, fluoxetine retains competitive advantages due to:

• Well-established efficacy and safety profile
• Cost-effectiveness owing to generics
• Extensive clinical experience among prescribers

Market Challenges and Opportunities

Challenges include increasing concerns over serotonergic syndrome, side effects, and evolving treatment guidelines favoring individualized therapy. Nonetheless, opportunities lie in:

• Repurposing fluoxetine for non-psychiatric indications, such as cancer cachexia and menopausal symptoms, based on ongoing research
• Developing extended-release formulations and combination therapies
• Exploring digital health integration for adherence monitoring

Future Market Projection

The global fluoxetine market is projected to grow at a compounded annual growth rate (CAGR) of approximately 3-4% through 2030, driven by expanded indications, formulation innovations, and emerging markets.

• By 2030, the market value is anticipated to reach roughly $6 billion, with North America maintaining dominant share, though Asia-Pacific will realize the highest growth rates, potentially surpassing traditional markets owing to demographic and healthcare expansion.

• The increasing focus on mental health and the proliferation of telemedicine platforms are expected to facilitate better access to treatment, further boosting demand.

Innovation and Future Outlook

Pipeline and Innovative Therapies

Apart from established uses, research exploring fluoxetine’s effects on neuroplasticity and neurogenesis may unlock novel therapeutic pathways. The convergence of pharmacology with digital therapeutics promises to reshape delivery and adherence models.

Regulatory Environment and Healthcare Policy

Global efforts to destigmatize mental health and integrate mental health services into mainstream healthcare will augment the prescription landscape for fluoxetine. Regulatory bodies enhancing approval pathways for repurposed drugs, coupled with accelerated approval processes for unmet medical needs, support future growth.

Potential Disruptors

Emerging therapeutics, such as psychedelic-assisted therapies (e.g., psilocybin), might impact the traditional antidepressant market. Nonetheless, fluoxetine’s long-standing safety record and familiarity position it as a complementary, foundational therapy.

Key Takeaways

• Clinical Trials: Ongoing research is expanding fluoxetine’s indications into neurodevelopmental and neurodegenerative disorders, with promising early-phase results. Controlled-release formulations and combination therapies are under active investigation to improve efficacy and adherence.

• Market Dynamics: The global market remains sizable, dominated by generics and mature markets, yet emerging markets and novel formulations present growth opportunities. The CAGR of 3-4% suggests steady expansion through 2030.

• Regulatory and Innovation Trends: Regulatory bodies favor accelerated pathways for repurposed or novel formulations, fostering innovation. Future therapies focusing on neuroplasticity and personalized medicine are poised to differentiate fluoxetine further.

• Strategic Outlook: Manufacturers should capitalize on ongoing clinical validation and market expansion into neuropsychiatric and neurodevelopmental areas while investing in formulation and delivery innovations.

Concluding Remarks

Fluoxetine Hydrochloride continues to assert its clinical and commercial relevance. Strategic engagement with emerging indications, formulation advancements, and expanding global access will determine its sustained market leadership. The evolving scientific landscape and regulatory incentives present promising avenues for growth, ensuring fluoxetine remains integral in mental health treatment paradigms well into the next decade.

---

FAQs

1. What are the latest developments in clinical trials for fluoxetine?
Recent trials are exploring fluoxetine’s efficacy in ASD, PTSD, and neurocognitive disorders, alongside innovations in controlled-release formulations aimed at improving adherence and reducing side effects.

2. How is the global market for fluoxetine expected to evolve over the next decade?
The market is projected to grow modestly at 3-4% CAGR through 2030, driven by expanded indications, emerging markets, and formulation innovations, reaching approximately $6 billion in value.

3. Are new formulations of fluoxetine available or in development?
Yes. Controlled-release, once-weekly formulations are emerging, offering improved compliance. Research continues into combination therapies and novel delivery methods.

4. What challenges does fluoxetine face in maintaining its market relevance?
Competition from newer antidepressants, concerns over side effects, and emerging alternative therapies such as psychedelics pose challenges. However, its long-established safety profile remains a key advantage.

5. What are potential new applications of fluoxetine beyond depression?
Research indicates potential in neurodevelopmental disorders like ASD, neurodegenerative diseases, and certain cancer-related and menopausal symptoms, expanding its therapeutic reach.

---

Sources:

1. Neuropsychopharmacology (2022). "Efficacy of fluoxetine in ASD: A randomized trial."
2. Market research reports and industry data (2022). "Global antidepressant market analysis."
3. U.S. Food and Drug Administration (FDA) records and approvals (2023).
4. ClinicalTrials.gov database.
5. Pharma Market Outlook reports (2022).